Home › Research › Topics › cerebral-amyloid-angiopathy
cerebral-amyloid-angiopathy
5 studies tagged cerebral-amyloid-angiopathy, dated 2007-10-31 to 2023-10-31. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics 2023-10-31
- Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis 2022-02-14
- Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy 2022-01-01
Studies
5 studies carry this tag.
Date range
2007 to 2023
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 1
- Brain and behavior 1
- Frontiers in aging neuroscience 1
- Journal of Alzheimer's disease : JAD 1
- Neuropathology and applied neurobiology 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Plasma amyloid beta (Aβ) and tau are emerging as accessible biomarkers for Alzheimer's disease (AD).
-
The analyzed parameters differentiate between controls and CAA with clinically useful accuracy (AUC > ∼0.85) but not between CAA and AD.
-
CSF biomarkers may improve the accuracy of the modified Boston criteria with altered profile in 85% of the patients fulfilling revised Boston criteria for probable CAA.
-
Overall, these results support the vervet as a non-human primate model of amyloid-related neurodegeneration, such as Alzheimer's disease and cerebral amyloid angiopathy, and highlight Aβ 1-40 and p-tau 181 as potentially valuable biomarkers of these processes.
-
Our findings indicate that ACE-1 activity is increased in AD, in direct relationship to parenchymal Abeta load.